0001214659-21-004267.txt : 20210416
0001214659-21-004267.hdr.sgml : 20210416
20210416160755
ACCESSION NUMBER: 0001214659-21-004267
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210415
FILED AS OF DATE: 20210416
DATE AS OF CHANGE: 20210416
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bhavnagri Veer
CENTRAL INDEX KEY: 0001808980
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38693
FILM NUMBER: 21831555
MAIL ADDRESS:
STREET 1: C/O ALLOGENE THERAPEUTICS, INC.
STREET 2: 210 E. GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Allogene Therapeutics, Inc.
CENTRAL INDEX KEY: 0001737287
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 823562771
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 210 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 457-2700
MAIL ADDRESS:
STREET 1: 210 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
marketforms-52267.xml
PRIMARY DOCUMENT
X0306
4
2021-04-15
0001737287
Allogene Therapeutics, Inc.
ALLO
0001808980
Bhavnagri Veer
210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO
CA
94080
false
true
false
false
General Counsel
Common Stock
2021-04-15
4
M
false
10000
2.27
A
431353
D
Common Stock
2021-04-15
4
S
false
9394
32.0138
D
421959
D
Common Stock
2021-04-15
4
S
false
606
32.6398
D
421353
D
Stock Option (Right to Buy)
2.27
2021-04-15
4
M
false
10000
0.00
D
2028-06-25
Common Stock
10000
142300
D
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.56 to $32.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.57 to $32.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
25% of the shares subject to the stock option vested on April 6, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.
Veer Bhavnagri
2021-04-16